LinkedIn

Dr. Boyle is a senior executive with over 30 years of pharmaceutical and biotechnology industry experience including leadership roles in private start-up and multinational companies. He is currently a Senior Research Fellow of BioAtla Inc. {BCAB; NASDQ] and Chief Science Officer of Himalya Therapeutics (SEZG). He previously served as Chief of translational Medicine at BioAtla and was an Associate Professor of Medicine at UCLA David Geffen School of Medicine and Director of the DGSOM CTSI Accelerator. He is a founder of AnaptysBio [ANAB; NASDQ], a therapeutic antibody company based on somatic hypermutation technology, where served as President and Chief Science Officer. Before AnaptysBio, he was the Chief Scientific Officer for Auxeris Therapeutics and was Vice President of Biology at Protein Pathways. Prior to these roles, Dr. Boyle was at Amgen, Inc. for over 11 years, and was involved in the discovery and development of novel protein and small molecule candidate therapeutics. He was formerly Director of Discovery Research and led the basic research effort as part of the preclinical and clinical development of OPG and derivative RANKL antagonists. His research in this area helped to define the RANK-RANKL signaling pathway, and he led the discovery and characterization of AMG 162 (Denosumab®), a RANKL-targeted human monoclonal antibody therapeutic approved in the U.S. and E.U. for osteoporosis (Prolia®) and for bone metastasis and skeletal related events (Xgeva®). Dr. Boyle was instrumental in organizing and leading the research effort behind their rheumatology franchise, and in developing a corporate partnership with Abgenix, which resulted in the isolation of AMG 162 and Amgen’s first antibody IND filing. Dr. Boyle holds a Doctoral degree in Experimental Pathology from the UCLA School of Medicine and was a Howard Hughes Medical Institute Postdoctoral Fellow of the Life Sciences Research Foundation, at the Salk Institute in La Jolla.